FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
9 letters match. Newest first.
-
BiologicsTides Medical LLC
FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.
High risk -
BiologicsMicrovascular Tissue, Inc.
FDA says Microvascular Tissue's mVASC wound product is an unapproved drug and unlicensed biologic, made without validated processes.
High risk -
BiologicsBioXtek LLC
FDA says BioXtek's amniotic membrane products are unapproved new drugs and unlicensed biological products.
High risk -
DrugsDermaRite Industries, LLC
DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.
High risk -
DevicesQianjiang Kingphar Medical Material Co Ltd.
FDA warned Chinese device maker Qianjiang Kingphar that dirty cleanrooms and weak environmental controls make its masks, dressings, wraps and drapes adulterated.
High risk -
DevicesThe Richline Group, Inc.
FDA warns Richline Group over unapproved Inverness ear care products and quality-system failures.
High risk -
BiologicsNuVida Medical LLC
FDA says NuVida Medical sells unapproved, unlicensed tissue products for non-homologous wound care uses.
High risk -
DevicesAG Essence, Inc.
FDA warned AG Essence that its Banda-SiL silver wound gels are adulterated and misbranded because they are sold without required FDA marketing clearance.
High risk -
DevicesIntegra LifeSciences Corporation
FDA warned Integra LifeSciences over collagen-based medical devices made in Boston after an inspection found quality-system failures and endotoxin testing problems.
High risk